Development of the norfolk quality of life tool for assessing patients with neuroendocrine tumors

Pancreas

Volumn 38, Issue 3, 2009, Pages

  Vinik, Etta ^a   Carlton, Cristi A ^b   Silva, Maria P ^a   Vinik, Aaron I ^a,b  

^a Department of Medicine   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATTITUDE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTENT VALIDITY; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; DELPHI STUDY; DEPRESSION; FACTORIAL ANALYSIS; FEMALE; FLUSHING; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; INTERNAL CONSISTENCY; LOGISTIC REGRESSION ANALYSIS; MALE; NEUROENDOCRINE TUMOR; NORFOLK QUALITY OF LIFE TOOL; PHYSICAL ACTIVITY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REPRODUCIBILITY; RESPIRATORY TRACT DISEASE; SENSITIVITY AND SPECIFICITY; TEST RETEST RELIABILITY; AGED; METHODOLOGY; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; STANDARD; STATISTICAL MODEL; VALIDATION STUDY;

AGED; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROENDOCRINE TUMORS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 65549161382     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819b6441     Document Type: Article

References (19)

1. Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42(4):477-484.
2. Aaronson NK, Cull A,Kaasa S.The EORTC modular approach toquality of life assessment in oncology. Int J Ment Health. 1994;23:75-96.
3. Osoba D, Aaronson N, Zee B. Modification of the EORTC QLC-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res. 1997;6:103-108.
4. Staquet MJ, Hays RD, Fayers PM. Quality of Life Assessment in Clinical Trials: Methods and Practice. 1st ed. New York, NY: Oxford University Press; 1998.
5. Knox CD, Feurer ID, Wise PE, et al. Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg. 2004;8(6):653-659.
6. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497-508.
7. Radloff LS. The CES-D Scale. Appl Psychol Meas. 1997;1(3):385-401.
8. Woltering EA, Hilton RS, Zolfoghary CM, et al. Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas. 2006;33(3):250-254.
9. Korse CM, Bonfrer JMG, Aaronson NK, et al. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology. Published online, October 7, 2008.
10. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol. 2007;25(4):424-430.
11. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24(5): 451-463.
12. Penniston KL, Nakada SY. Health related quality of life differs between male and female stone formers. J Urol. 2007;178(6):2435-2440.
13. Simson U, Nawarotzky U, Porck W, et al. Depression, anxiety, quality of life and type D pattern among inpatients suffering from diabetic foot syndrome. Psychother Psychosom Med Psychol. 2008;58(2):44-50.
14. Ribu L, Hanestad BR, Moum T, et al. Health-related quality of life among patients with diabetes and foot ulcers: association with demographic and clinical characteristics. J Diabetes Complications. 2007;21(4):227-236.
15. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997; 349(9063):1436-1442.
16. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
17. Murray CJL, Lopez AD. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996. Ref Type: Magazine Article.
18. Sorensen VR, Mathiesen ER, Watt T, et al. Diabetic patients treated with dialysis: complications and quality of life. Diabetologia. 2007;50(11):2254-2262.
19. Vinik A, O'Dorisio T, Woltering E, et al. Neuroendocrine Tumors: a Comprehensive Guide to Diagnosis and Management. 1st ed. Inglewood, CA: Interscience Institute; 2006.